The Epsilon Group (TEG) is a modeling, analytics, and simulation services company committed to improving the understanding and management of diabetes mellitus with the ultimate goal of improving healthcare quality and delivery. To this end, TEG provides proprietary bio-simulation services and software (SAAM II, T1DMS, and DMMS) which enable physiologically-based modeling of a wide range of problems in the lab and translational research arena.
TEG’s primary area of expertise is glucose-insulin metabolism in Type 1, Type 2 and Pre- Diabetes. TEG offers simulation and consulting services for development and optimization of diabetes-specific treatments, clinical and life-style protocols, and monitoring devices using a unique and specialized modeling software. Epsilon features the Type 1 Diabetes Metabolic Simulator (T1DMS) with the FDA-accepted in silico patient population, and the DMMS.R with the additional T2DM and Pre Diabetes in silico populations.
How TEG Solutions can help you
Life Sciences and Pharma
Develop physiologically-based pharmacokinetic/pharmacodynamic drug models, test control algorithms, simulate clinical trials and examine outcomes to optimize therapy and eliminate non-viable solutions cost-effectively, early in the R&D phase.
Simulate interventions and self-management of diabetes and related disease processes to optimize care delivery and understanding of disease management.
Utilize latest compartmental and mathematical modeling techniques to educate current and future healthcare providers, engineers and researchers across many disciplines.